2022 SPIE and Photonics Media Prism Awards Celebrate Innovative Photonics Technologies
Earlier this evening, following a festive reception during SPIE Photonics West, SPIE, the international society for optics and photonics, and Photonics Media recognized the top optics and photonics products on the market with their industry-focused Prism Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005964/en/
2022 SPIE and Photonics Media Prism Awards celebrate innovative photonics technologies at SPIE Photonics West. (Graphic: Business Wire)
The 14th annual ceremony showcased a dynamic range of companies — from Luxexcel, PlenOptika, and Lumotive, to SWIR, LightPath Technologies, and ColdQuanta — applying innovative and creative solutions to critical problems in areas such as augmented and virtual reality, biomedical devices, autonomous vehicles, quantum, and industrial lasers. In addition, the 2021 Prism Award winners of last year’s virtual ceremony were recognized in person at the beginning of the program.
Each year, the Prism Awards reflect the latest exciting developments, exponential growth, and rich technical innovations across photonics and photonics-enabled industries. For consideration in this year's awards, SPIE received 120 applications from 18 countries.
Finalists and winners were selected by a panel of international judges who leveraged the knowledge and acumen of leaders from across the technology commercialization and funding sectors. The distinguished judges’ roster included MKS Instruments’ Marc D. Himel, the FDA’s Zane Arp, Femto Blanc’s Uri Abrams, iFocus’ Adi Diner, Berkeley Catalyst Fund’s Laura Smoliar, Engender Technologies’ Cather Simpson, Luminate Accelerator’s Sujatha Ramanujan, Notal Vision’s Nishant Mohan, Teledyne Princeton Instruments’ Jason McClure, and Chromacity’s Shahida Imani.
"We are particularly delighted to be celebrating our Prism Award winners in person this year,” said SPIE CEO Kent Rochford. "These companies with their scientists and engineers — and I am including the award finalists as well — are ensuring that key technologies and products are reaching, energizing, and continually growing the photonics market. Their critical, innovative work is impacting lives across the globe.”
"Each year, the Prism Awards singles out the very brightest innovations in a highly innovative industry and, despite a global pandemic, supply chain issues, and other challenges over the past year, the 2022 winners still found a way to advance the field of photonics in important and remarkable ways,” said President and CEO of Photonics Media Tom Laurin. “We extend our congratulations to each of this year’s winners, who deserve our industry's recognition for their advancements in transportation, biomedicine, research, sensing, and quantum technology."
Below is the complete list of the award categories and the winners:
- Augmented & Virtual Reality: Luxexcel
- Autonomous Vehicles: Lumotive
- Better Sensing: SWIR Vision Systems
- Biomedical Devices: PlenOptika
- Displays: BRELYON
- Industrial Lasers: Civan Lasers
- Manufacturing & Test: LightPath Technologies
- Quantum: ColdQuanta
- Scientific Lasers: Stuttgart Instruments
- Software: Zemax
To find out more about the Prism Awards, please visit our website.
About Photonics Media
Photonics Media publishes print and digital business-to-business magazines, buyers' guides, websites, e-newsletters, webinars, virtual conferences, and podcasts for individuals working with light-based technologies in the photonics industry. A pioneering publisher in the discipline of photonics, Photonics Media has built a large global audience comprising academics and researchers, manufacturers, and end-users. Over the past six decades, the company has fostered a tradition of innovation that has defined the industry. As its publications grow — following the technology into an ever-widening range of applications — the company adheres to a philosophy of editorial quality and integrity, maintaining an international reputation for leadership in photonics. www.photonics.com.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005964/en/
Contact information
Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom